Core Viewpoint - The article suggests that while AI stocks are experiencing a downturn, biotech stocks, particularly Eli Lilly, present a compelling investment opportunity due to their potential for AI-assisted drug discovery and strong market positions in existing drug markets [1]. Company Analysis - **Eli Lilly (LLY)**: - The stock has seen a decline of approximately 7% year-to-date, but it remains a leader in the GLP-1 drug market with products like Zepbound and Mounjaro [1]. - Eli Lilly's partnership with Nvidia, valued at $1 billion, aims to enhance AI-assisted drug discovery, positioning the company for future growth [1]. - The stock is currently trading at a forward price-to-earnings (P/E) ratio of under 30, which is considered attractive given its potential for AI integration and existing revenue streams from GLP-1 drugs [1]. Industry Insights - The article highlights a shift in investor sentiment away from AI stocks due to rising capital expenditures and concerns over return on investment (ROI) [1]. - Biotech is identified as a sector that could benefit significantly from AI advancements, with the potential for transformative impacts on drug discovery and development processes [1]. - The article emphasizes the importance of diversifying investments into biotech as a counterbalance to the volatility seen in AI-driven tech stocks [1].